An Open-label Study Evaluating Ofatumumab Treatment Effectiveness and PROs in Subjects With RMS Transitioning From Fumarate-based RMS Approved Therapies or Fingolimod to Ofatumumab

Inclusion Criteria: * Diagnosis of MS according to the 2017 Revised McDonald criteria * Relapsing MS: relapsing forms of MS (RMS) including RMS and secondary progressive MS (SPMS) * Disability status at screening defined by Expanded Disability Status Scale (EDSS) score of 0 to 4 (inclusive) * MS treatment history with a maximum of 3 Disease Modifying Therapies (DMTs), where all fumarates are considered as one DMT * Subject transitioning from either any fumarate-based RMS approved therapies, such as dimethyl fumarate (DMF) or diroximel fumarate (DRF), or fingolimod which was administered for a period of at least 6 months, as their last DMT before first study drug administration * Breakthrough disease activity while the participant was adequately using fumarates or fingolimod prior to transitioning for a minimum of 6 months as evidenced by one or more clinically reported relapses or one or more signs of Magnetic Resonance Imaging (MRI) activity (e.g. Gd+ enhancement, new or enlarging T2 lesions) * Neurologically stable within one month prior to first study drug administration Exclusion Criteria: * Subjects with primary progressive MS or SPMS without disease activity * Subjects meeting criteria for neuromyelitis optica * Disease duration of more than 10 years since diagnosis * Pregnant or nursing (lactating) women * Women of child-bearing potential unless they are using highly effective forms of contraception during dosing and for at least 6 months after stopping study medica…